Clinical Trials on Melanoma in Situ

Total 68837 results

NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Dana-Farber Cancer Institute
Celldex Therapeutics

Recruiting

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Melanoma | Metastatic Melanoma

United States
Uppsala University

Recruiting

A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma (TRIM)

Malignant Melanoma

Sweden
Pfizer

Completed

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Metastatic Melanoma

United States
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Elios Therapeutics, LLC
LumaBridge

Completed

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Metastatic Melanoma

United States
Castle Biosciences Incorporated

Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)

Cutaneous Melanoma

United States
AstraZeneca

Completed

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) (SUMIT)

Uveal Melanoma | Metastatic

United States, Czech Republic, Spain, United Kingdom, Germany, Canada, Israel, Netherlands, Belgium, France, Finland
National Cancer Institute (NCI)
GlaxoSmithKline; Novartis Pharmaceuticals

Active, not recruiting

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...

United States
Duke University

Not yet recruiting

Eye Plaque Brachytherapy for Ocular Melanoma (PROMPT)

Ocular Melanoma
Odense University Hospital
Aarhus University Hospital; University of Copenhagen; Aalborg University Hospital

Recruiting

Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy

Malignant Melanoma

Denmark
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Advanced Melanoma

China
Centre Hospitalier Universitaire de Nice

Recruiting

Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors (mela-quantif)

Melanoma (Skin)

France
Centre Hospitalier Universitaire de Nice

Recruiting

Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma (BMUMM)

Cutaneous Melanoma

France
John Kirkwood
Bristol-Myers Squibb; Secura Bio, Inc.

Recruiting

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Unresectable Melanoma

United States
The Methodist Hospital Research Institute
Genentech, Inc.

Recruiting

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Cutaneous Melanoma

United States
University of Louisville

Recruiting

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Cutaneous Melanoma

United States
University Hospital, Essen

Completed

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Metastatic Melanoma

United States
Ultimovacs ASA

Completed

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Malignant Melanoma

United States, Belgium, United Kingdom, Norway
Novartis

Completed

Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients

Metastatic Melanoma

Switzerland
Takara Bio Inc.

Completed

A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Japan
European Organisation for Research and Treatment...
Northwell Health Cancer Institute

Not yet recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma (ATOM)

Uveal Melanoma
Medical University of Vienna

Recruiting

Retrospective Register for Uveal Melanoma

Uveal Melanoma

Austria
Institut Curie

Recruiting

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) (SALOME)

Uveal Melanoma

France
Institut Curie

Completed

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

Uveal Melanoma

France
Columbia University
Pfizer

Completed

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Uveal Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Uveal Melanoma

United States
Radboud University Medical Center
Rotterdam Eye Hospital

Terminated

Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Uveal Melanoma

Netherlands
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Uveal Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Treatment With Intravitreal Avastin for Large Uveal Melanomas

Uveal Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
PrimeVax Immuno-Oncology Inc.
Walter Reed Army Institute of Research (WRAIR)

Not yet recruiting

Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma

Advanced Melanoma
Yousef Zakharia
University of Iowa; Exelixis

Recruiting

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Advanced Metastatic Melanoma

United States
Chinese University of Hong Kong

Completed

Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Acral Lentiginous Melanoma

Hong Kong
Carman Giacomantonio
Nova Scotia Health Authority

Withdrawn

The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma

Cutaneous Metastatic Melanoma
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
Wilson Miller

Active, not recruiting

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Metastatic Malignant Melanoma

Canada
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Stage IV Melanoma

United States
Lynn E. Spitler, MD
University of California, San Francisco

Completed

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)

Malignant Melanoma, Metastatic

United States
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
Takara Bio Inc.
Theradex

Completed

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Malignant Melanoma

United States
Angimmune LLC
James Graham Brown Cancer Center

Unknown

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Stage IV Melanoma

United States
John P. Fruehauf

Completed

Disulfiram in Patients With Metastatic Melanoma

Stage IV Melanoma

United States
Eisai Inc.
Quintiles, Inc.

Completed

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Stage IV Melanoma

United Kingdom, United States, Spain, Germany, Italy
Hoffmann-La Roche

Completed

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Malignant Melanoma, Neoplasms

Russian Federation, Korea, Republic of, Israel, South Africa, Belarus
Philogen S.p.A.

Completed

Intratumoral Administration of L19IL2/L19TNF

Malignant Melanoma, Skin

Italy
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States

Clinical Trials on Melanoma in Situ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations